GSK's anti-BCMA drug hits goal in pivotal multiple myeloma test

A phase 2 trial of GlaxoSmithKline’s BCMA drug has hit its primary endpoint, keeping Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.